Tuberc Respir Dis > Volume 67(5); 2009 > Article
Tuberculosis and Respiratory Diseases 2009;67(5):445-448.
DOI: https://doi.org/10.4046/trd.2009.67.5.445    Published online November 1, 2009.
Recurrent Erlotinib-Induced Interstitial Lung Disease on Non-Small Cell Lung Cancer.
Sang Don Park, Areum Kim, Jin Seok Park, Chun Ho Shin, Hae Sung Nam, Lucia Kim, Jae Wha Cho, Jeong Sun Ryu, Seung Min Kwak
1Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea. smkwak@inha.ac.kr
2Department of Pathology, Inha University College of Medicine, Incheon, Korea.
Abstract
Erlotinib (Tarceva(R)) has been considered to be a new, promising oral chemotherapy agent for local advanced or metastatic non-small cell lung cancer (NSCLC). Erlotinib is regarded as relatively safe, but interstitial lung disease (ILD) related to erlotinib has been reported on an infrequent basis in Asia. We report an histologically confirmed case of recurrent erlotinib-induced ILD. Although, the patient was highly responsive to the first erlotinib treatment, the therapy was discontinued due to erlotinib-induced ILD. After intravenous high dose methylpredinisolone treatment, ILD was improved rapidly by radiologic studies, but the particular lung cancer re-emerged. We restarted the patient erlotinib on low-dose oral methylpredinisolone, resulting in a recurrence of erlotinib-induced ILD. Our case suggests that re-administration of erlotinib should be performed on a limited basis in patients that have developed ILD on previous use, even if a therapeutic effect can be estimated.
Key Words: Erlotinib, Lung Diseases, Interstitial, Carcinoma, Non-Small-Cell Lung


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2024 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next